hotspot -WSS

hotspot

author：leisure time 2025-09-30 00:38:01 - browse：566

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： FDA approves Recor Medical high blood pressure device

WSS

Timeline: Key moments in fight for gay rights

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Novo: Oral version of Ozempic leads to 15% weight loss

A clever new way to fix Medicaid and graduate medical education

Patients, doctors are clashing about side effects of hormonal birth control

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Just how powerful is the placebo effect?

Tori Bowie and the unacceptable rates of Black maternal death

Xenotransplantation trials will require adjusting expectations, experts say

Wildfire smoke exposes gaps in outdoor worker protections

A clever new way to fix Medicaid and graduate medical education

Moonlake's readout produced a cash windfall. Risks remain

Biogen nominates mother of director’s child to replace him on board

After affirmative action ruling, medical educators look to 'holistic review'

Inside the rise of 'mukbang' eating videos

focus

The thinking behind the controversial eating disorder chatbot Tessa

STAT Executive Editor Rick Berke on STAT's 8th birthday

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Biogen nominates mother of director’s child to replace him on board

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

MoonLake credibility takes another hit with mid

focus

entertainment

explore

leisure time